• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

    5/28/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email

    TORONTO and GLIL YAM, Israel, May 28, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announces that it has applied for a voluntary delisting of its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). The delisting from the CSE will not affect the Company's listing on NASDAQ and its Shares will continue trading on the NASDAQ under the symbol "IMCC".

    IM Cannabis Corp Logo

    The Company is entertaining potential transactions that, if completed while the Company is listed on the CSE, would require the Company to incur unnecessary burdensome costs, approvals and delay. The Company believes that the trading volume of its Shares on the CSE no longer justifies the expenses, administrative efforts, and regulatory burdens required to maintain a dual listing. The Company also believes that delisting from the CSE will create a central marketplace for its Shares on the Nasdaq and ultimately benefit the long-term liquidity and shareholder value of the Company. All shareholders can continue trading IMC's shares on Nasdaq under the symbol "IMCC".

    The Company is grateful to the CSE for providing its initial opportunity to access public markets. It is expected, subject to approval from the CSE, that the close of business on Monday, June 2, 2025, will be the final trading day for IMC on the CSE.

    About IM Cannabis Corp.

    IMC (NASDAQ:IMCC) (CSE:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

    The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

    Forward Looking Information

    This press release contains certain "forward-looking statements" within the meaning of Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "believes", "anticipates", "expects", "is expected", "scheduled", "estimates", "pending", "intends", "plans", "forecasts", "targets", or "hopes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "will", "should" "might", "will be taken", or "occur" and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements that address activities, events or developments that the Company expects or anticipates will or may occur in the future including the Company's potential delisting from the CSE, the Company's expectation that its Shares will be delisted from the CSE; the Company ceasing to file reports to the CSE after delisting; and the Company's expectation that its Shares will continue trading on the NASDAQ.

    The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include risks associated with the Company's potential delisting from the CSE; the Company ceasing to file reports to the CSE; the Company's ability to relist on the CSE in the future; the timing and receipt of certain approvals from the CSE pertaining to the delisting; and the anticipated benefits associated with delisting.

    The reader is urged to refer to additional information relating to IMC, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

    This list of risk factors should not be construed as exhaustive. The Company does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

    Company Contact:

    Anna Taranko, Director Investor & Public Relations

    IM Cannabis Corp.

    +49 157 80554338

    [email protected] 

    Oren Shuster, CEO

    IM Cannabis Corp.

    +972-77-3603504

    [email protected]

    Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/im-cannabis-announces-plans-to-voluntarily-delist-from-the-canadian-securities-exchange-302466961.html

    SOURCE IM Cannabis Corp.

    Get the next $IMCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH Capital initiated coverage on IM Cannabis with a new price target

    ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

    10/5/21 7:57:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IMC Mortgage Co

    Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

    7/14/21 8:40:32 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IM Cannabis with a new price target

    Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

    7/14/21 7:01:53 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

    TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

    8/4/25 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    SEC Filings

    View All

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    8/13/25 5:03:53 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form F-3 filed by IM Cannabis Corp.

    F-3 - IM Cannabis Corp. (0001792030) (Filer)

    8/13/25 4:02:13 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    8/12/25 8:15:25 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

    TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

    8/4/25 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IM Cannabis Corp.

    SC 13G - IM Cannabis Corp. (0001792030) (Subject)

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

    SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

    2/8/23 1:29:15 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

    10/10/23 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

    Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

    1/13/22 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care